Teva Pharmaceutical Industries

Aging Demographics And Biosimilar Launches Will Transform Healthcare Demand

AnalystConsensusTarget

Not Invested

Consensus Narrative from 9 Analysts

Published

23 Apr 25

Updated

15 Aug 25

AnalystConsensusTarget's Fair Value

US$23.44

23.0% undervalued

15 Aug

US$18.06

-1.3%

10.0%

Author's Valuation

US$23.4

23.0% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates1

Shared on01 May 25
Fair value Decreased 0.50%

AnalystConsensusTarget Fair Value

US$23.4

23.0% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

2.35%

Pharma revenue growth rate

0.57%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

8.34%

Calculation

US$1.46b

Earnings '28

24.29x

PE Ratio '28

US$35.49b

Market Cap '28

US$35.49b

Market Cap '28

1.19b

No. shares '28

US$29.80

Share Price '28

US$29.80 Share Price '28

Discounted to 2025 @ 8.36% p.a.

US$23.43

Fair Value '25

Aging Demographics And Biosimilar Launches Will Transform Healthcare Demand

Shared on01 May 25Fair value Decreased 0.50%

Shared on01 May 25
Fair value Decreased 0.50%